






3/4

# As the use of GLP1 therapy has increased, the number of FreeStyle Libre users has continued to grow rapidly



a. Libre users who are Type 1 or Type 2 diabetics who inject insulin multiple times per day


b. Libre users who are Type 2 diabetics that are ~~basal~~ insulin users or non-insulin users

Data in millions. Based on company model.





# GLP-1 adherence (number of days on GLP1 therapy) is higher for those who also use FreeStyle Libre



a. Type 2 intensives inject insulin multiple times per day

b. Type 2 non-intensives include basal-only insulin users and non-insulin users

$\frac{3}{4}$

# Overview Of data source

- ¾ This analysis was based on robust data sets that capture patient claims data for the entire U.S. retail pharmacy channel
- ¾ The U.S. retail pharmacy channel reflects the pharmacy insurance coverage for patients covered by Commercial insurance plans, Medicare Advantage plans, Managed Medicaid and Medicaid insurance plans. In addition, it covers other payment types such as Cash pay programs
- ¾ The U.S. retail pharmacy channel covers approximately 280 million people and represents approximately 2/3 of all FreeStyle Libre users in the U.S. today



